论文信息 - Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level - 字舞流文

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level

H. Kantarjian | E. Jabbour | W. Stock | D. DeAngelo | S. O'brien | A. Advani | E. Vandendries | R. Cassaday | M. Stelljes | A. Laird | Tao Wang | K. Nguyen | B. Sleight | L. Paccagnella